101513-78-4Relevant articles and documents
Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections
Betson, Mark,Bingham, Matilda,Doyle, Paul,Hallworth, Sebastian,Harvey, Rebecca,Huxley, Anthony,Kirk, Ralph,Moat, John,Nelson, Gary,Pesnot, Thomas,Tait, Michael
supporting information, (2020/08/17)
Delafloxacin, a fourth-generation anionic fluoroquinolone (FQ) was approved in 2019 for community acquired bacterial pneumonia (CARP). It has broad spectrum activity and an improved class-related toxicity profile. However, it has recently failed a Phase 3
Preparation method of Delafloxacin and intermediates thereof
-
Paragraph 0018; 0041-0043, (2018/08/04)
The invention relates to a preparation method of Delafloxacin and intermediates thereof. The method comprises the following steps: firstly, taking 3-chloro-2,4,5-fluorobenzoic acid (compound 1) as a raw material and reacting the raw material with thionyl
Synthesis and bioactivity of 6-phenyl-4,5-dihydro-3(2H)-pyridazinone derivatives
Wang, Teng,Dong, Ying,Wang, Li-Chen,Chen, Zhen
, p. 641 - 646 (2008/03/11)
A series of 6-phenyl-4,5-dihydro-3(2H)-pyridazinone derivatives was prepared and examined for cardiotonic activity. The structures of these new pyridazinone derivatives were confirmed by IR, 1H-NMR and mass spectrum. The cardiotonic activities of these compounds were studied on isolated perfused toad heart and compared with the activity of levosimendan (CAS 141505-33-1). Compound 5a emerged as the most interesting compound in this series with potential cardiotonic activity. ECV Editio Cantor Verlag.